BiotechTube

Dapoxetine

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sexual Dysfunction

Conditions

Sexual Dysfunction, Ejaculation

Trial Timeline

Nov 1, 2004 → Aug 1, 2005

NCT ID
NCT00210613

About Dapoxetine

Dapoxetine is a phase 3 stage product being developed by Johnson & Johnson for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00210613. Target conditions include Sexual Dysfunction, Ejaculation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT00210704Phase 3Completed
NCT00229073Phase 3Completed
NCT00210613Phase 3Completed

Competing Products

18 competing products in Sexual Dysfunction

See all competitors
ProductCompanyStageHype Score
Gardasil VaccineMerckPre-clinical
23
sildenafilPfizerApproved
84
sildenafilPfizerPhase 2
51
CP-866,087 + CP-866,087 + CP-866,087 + PlaceboPfizerPhase 2
51
PF-00446687 + PlaceboPfizerPhase 2
51
BremelanotidePfizerPhase 2
51
Sildenafil 100 mg + PlaceboPfizerPhase 2
51
AlfuzosinSanofiApproved
84
AVANAFIL + placeboSanofiPhase 3
76
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
82
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
44
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
44
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
44
tibolone + estradiol-norethisteroneOrganonPhase 3
72
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
69
bremelanotidePalatin TechnologiesPhase 2
44
BremelanotidePalatin TechnologiesPhase 3
69
EVO100 + PlaceboEvofem BiosciencesPhase 3
69

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85